## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.8% below STRENGTH zone (4.0-10.0%); PEG 2.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($132.73)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Agilent Technologies Stock: Quiet Drift, Subtle Shifts – Is This Calm Before A Bigger Move?**
- Source: AD HOC NEWS | 20260102T065855 | Somewhat-Bullish | Relevance: 100%
- Agilent Technologies stock has been in a quiet equilibrium, trading in a tight range despite shifting end-market dynamics and recent analyst calls. While the past year shows a modest positive return for long-term investors, the company is managing through a cyclical trough in life science and diagnostics markets. Wall Street analysts show cautious optimism, with most issuing "Buy" or "Hold" ratings and price targets suggesting moderate upside as the company navigates recovery.

**2. Fenimore Asset Management Inc Acquires 405,620 Shares of Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20260101T101656 | Bullish | Relevance: 100%
- Fenimore Asset Management Inc significantly increased its stake in Agilent Technologies, Inc. (NYSE:A) by 224.2%, purchasing an additional 405,620 shares to hold a total of 586,500 shares valued at approximately $75.3 million. This makes Agilent its 27th largest holding, representing about 1.5% of Fenimore’s investment portfolio. Agilent Technologies recently reported strong Q3 earnings, beating EPS and revenue estimates, and raised its quarterly dividend.

**3. Boston Trust Walden Corp Sells 48,731 Shares of Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20251231T080730 | Somewhat-Bullish | Relevance: 100%
- Boston Trust Walden Corp reduced its stake in Agilent Technologies by 17.5%, selling 48,731 shares, bringing its total holding to 229,761 shares valued at approximately $29.49 million. Concurrently, insider selling by CEO Padraig Mcdonnell and VP Rodney Gonsalves amounted to 16,401 shares worth $2.47 million over the past 90 days. Despite the institutional and insider selling, Agilent reported strong quarterly results, beating EPS estimates and growing revenue by 9.4%, while analysts maintain a "Moderate Buy" rating with a consensus target price of $161.77.

**4. Fenimore Asset Management Inc Buys 6,629 Shares of Keysight Technologies Inc. $KEYS**
- Source: MarketBeat | 20260101T101826 | Neutral | Relevance: 73%
- Fenimore Asset Management Inc increased its stake in Keysight Technologies Inc. by 1.1% in the third quarter, purchasing 6,629 additional shares to hold a total of 632,432 shares. This makes Keysight Technologies the 16th-largest position in Fenimore's portfolio, representing approximately 2.2% of its total holdings. The article also notes Keysight's strong Q3 earnings, positive Q1 2026 guidance, a $1.5 billion stock repurchase authorization, and recent insider selling activities.

**5. Thermo Fisher stock jumps 2% to start 2026 as investors turn to Jan. 29 earnings**
- Source: ts2.tech | 20260103T015133 | Somewhat-Bullish | Relevance: 64%
- Thermo Fisher Scientific Inc (NYSE: TMO) shares rose 2.25% on the first trading day of 2026, outpacing the S&P 500. This outperformance comes as investors adopt a "buy the dip, sell the rip" mentality after a late-December market slide. All eyes are now on the company's Q4 and full-year 2025 earnings report scheduled for January 29, which will provide crucial insights into demand and the outlook for 2026.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $165 | $165 | 0% |
| 2025-12-09 | Goldman Sachs | $170 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | up | Overweight |
| 2025-12-09 | Goldman Sachs | init | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.16 elevated, pricing in significant growth expectations. Forward P/E 21.0x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $39.1B |
| Beta | 1.27 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.16 |
| Forward P/E | 21.0 |
| Current P/E | 23.2 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.7% to -0.8% (+3.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.8pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.9%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). RSI neutral at 41. OFD pattern: +MLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.78% (CS: 30) | Neutral |
| RSI_14 | 41.4 | Neutral |
| MACD Histogram | -0.12 | Bearish |
| vs SMA20 | 0.987x | Below |
| vs SMA50 | 0.954x | Below |
| vs SMA200 | 1.103x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $137.95
- **Stop Loss:** $132.73 (3.8% risk)
- **Target:** $143.17 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 275
- **Position Value:** $37,936.25
- **Portfolio %:** 37.94%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*